Navigation Links
Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
Date:7/17/2009

es, avoiding unnecessary treatments in patients who are unlikely to benefit," said Sean Harper.

This label update is specific to the utility of KRAS as a biomarker for Vectibix used as a monotherapy. In the combination chemotherapy setting, the Vectibix "181" and "PRIME (203)" trials will be the first prospective Phase 3 clinical studies testing the clinical utility of KRAS as a predictive biomarker in mCRC patients in earlier lines of therapy. Data from the "181" and "PRIME (203)" trials are expected in the third quarter of 2009.

This update follows recent KRAS related action from key cancer organizations, including the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). A Clinical Provisional Opinion (CPO) was issued by ASCO in January, where the organization recommended the use of the KRAS biomarker in selecting the appropriate patients for anti-EGFr antibody therapy. In November 2008, the NCCN announced updates to their Guidelines on Colon and Rectal Cancers. The guideline updates included the recommendation that a determination of the KRAS gene status of either the primary tumor or a site of metastasis should be part of the pre-treatment work-up for patients diagnosed with metastatic colorectal cancer.

About Colorectal Cancer

Colorectal cancer is the third most common cancer diagnosed in men and in women in the United States (U.S.). The American Cancer Society estimates that about 106,100 new cases of colon cancer and 40,870 new cases of rectal cancer will be diagnosed in 2009. Colorectal cancer is the second leading cause of cancer death among men and women in the U.S. and it has been estimated that more than 49,000 people will die from colorectal cancer in 2009. That means that one person in the U.S. dies of colorectal cancer every 9.3 minutes.

About Vectibix


'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Amgen Appoints Rebecca M. Henderson to the Companys Board of Directors
2. 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
3. AUDIO from Medialink and Amgen: Experts Agree Infection in Cancer Patients Impacts Treatment Success
4. Amgen to Present at the Goldman Sachs Global Healthcare Conference
5. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
6. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
7. Amgen Highlights Data to Be Presented at ASCO
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
10. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
11. Amgen Announces Webcast of 2009 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Glaser Pediatric AIDS Foundation (EGPAF) and the American Cancer ... to essential pain medications for people living with HIV ... Pain initiative, this new partnership will help improve efforts ... the country. , Swaziland has the highest HIV ... of adults ages 15-49 infected. Many of these individuals ...
(Date:7/29/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... Test instruments after processing to assure ... where it matters most – on the surgical ... premium domestic appliances, introduces ProCare Protein Check, a ... cleaned. The ProCare liquid is applied directly to ... After 3 minutes, users visually determine the presence ...
(Date:7/29/2014)... that death rates rise in association with extremely hot ... summer of 2003, for example, resulted in about 22,000 ... Alex-andra Schneider at the Institute of Epidemiology II at ... temperatures on the number of deaths caused by cardiovascular ... and low temperatures in the study. , "Our findings ...
(Date:7/29/2014)... July 29, 2014 Healthcare staffing ... 2014 Nurses of Tomorrow Scholarship Competition winners:, ... Reno, NV ,     Racheal D., Freshman, Cerritos ... Junior, Houston Community College in Houston, TX ... Week, Medical Solutions hosts the Nurses of Tomorrow ...
Breaking Medicine News(10 mins):Health News:New partnership to improve access to essential pain medications for people living with HIV 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Mortality rates increase due to extreme heat and cold 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2
... veterinarians with a new way to understanding and treating heartworm in ... ... -- Merial today announced the availability of an educational CD for ... of heartworm prevention and treatment in dogs. Launched at the North ...
... As the unemployment rate grows, so do,the numbers ... with the,loss of health insurance. COBRA continuation coverage can ... workers have the right to,purchase such coverage, only about ... high. A November 2008 study by non-profit advocacy group,Families ...
... companies pull products from shelves as FDA advises consumers ... while salmonella probe continues , , MONDAY, Jan. 19 (HealthDay ... peanut butter products continued without letup Monday, as more ... store shelves. , The actions followed a U.S. Food ...
... Jan. 19 The 66th Annual Golden Globe Awards ... smiles this year thanks to the Kari Feinstein,s 2009 ... of the style lounge included Paris Hilton, Jessica Alba ... Kellan Lutz (Emmett Cullen). Proceeds of the lounge supported ...
... Health Innovation Discusses the Impact of the Economic Crisis on ... A new report released today from the ... to health providers, has found that hospitals and health systems ... spending and unprofitable healthcare services as a result of the ...
... Jan. 19 Abbott announced today,that the ... status,under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) ... blood analyzer. , Cartridges for ... a patient,s,metabolic state within a few minutes. The ...
Cached Medicine News:Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 2Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 3Health News:Is Your Business Ready for the COBRA Premium Subsidy? 2Health News:Peanut Butter Product Recalls Mount 2Health News:Peanut Butter Product Recalls Mount 3Health News:Photos: Opalescence Treswhite Supreme Adds Glimmer to 'Twilight' Film Actor's Smile 2Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 2Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 3Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 4Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 3
(Date:7/29/2014)... and TORONTO ... Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical ... development of improved novel formulations and alternative ... announces expansion of its pharmaceutical development implementing ... direction includes large molecule drugs that will address ...
(Date:7/29/2014)... , July 29, 2014  Based on ... systems (PERS) market, Frost & Sullivan recognizes MobileHelp ... Award for Price Performance Value Leadership. MobileHelp,s leadership ... captures expectations for tech progression in personal emergency ... for these solutions. MobileHelp is at ...
(Date:7/29/2014)... Medical Corporation (Apex, TWSE: 4106), a leading player in the ... is appealing the judgment of the Regional Court of ... that found the headgear of certain mask models infringe a ... against various ResMed patents in major countries. Apex further reiterates ... ResMed filed the lawsuit with the Regional ...
Breaking Medicine Technology:EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3Apex Continues Fighting Against Patents to Free Up Competition 2
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
... and removal in the urinary tract. The nitinol ... shape following extreme torsion. The unique tipless design ... basket to open at the base of the ... reduces the likelihood of mucosal damage and perforation. ...
... Used for soft-tissue ... limited to paravaginal repairs, ... or rectocele. Surgisis® ES ... enhanced strength for intraoperative ...
... Used for temporary suprapubic urinary diversion ... puncture the bladder. The access sheath is ... Once the catheter is introduced, the access ... low-profile catheter support is included for external ...
... and a FAM-labeled probe targeting the VP1 gene ... ASR contains primers and a Texas Red-labeled probe ... an instrument that can detect FAM and Texas ... Analyte Specific Reagent* (ASR) program is comprised of ...
Medicine Products: